canrenone has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolignano, D; Chung, EY; Natale, P; Navaneethan, SD; Palmer, SC; Ruospo, M; Strippoli, GF | 1 |
| Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M | 1 |
1 review(s) available for canrenone and Disease Exacerbation
| Article | Year |
|---|---|
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bias; Calcium Channel Blockers; Canrenone; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone | 2020 |
1 trial(s) available for canrenone and Disease Exacerbation
| Article | Year |
|---|---|
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
Topics: Aged; Aldosterone; Biomarkers; Canrenone; Disease Progression; Double-Blind Method; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Ventricular Dysfunction, Left; Ventricular Remodeling | 2007 |